Answers are grounded in this paper and cite their sources.
Broadly neutralizing antibodies (bNAbs) are being developed for the prevention, treatment, and cure of HIV-1. The efficacy of a bNAb is dependent upon the susceptibility of an individual’s virus to the administered bNAb, which can be assessed phenotypically or genotypically. Both methods require cut-offs for susceptibility classification; however, clinical cut-offs for bNAb susceptibility have not been established. In this study, we assessed susceptibility to the two HIV-1 bNAbs 3BNC117 and 10–1074 among 59 newly diagnosed people living with HIV-1 using one phenotypic and four genotypic susceptibility assessment methods. We show that the methods employed and cut-offs assigned can greatly affect the susceptibility prediction. By evaluating the decay in plasma viral load for participants receiving 3BNC117 at ART initiation, clinically relevant cut-offs for susceptibility were identified using an exploratory approach, and application of these cut-offs resulted in 68%–76% of the viruses being correctly classified. No clinical data were available to set cut-offs for susceptibility to 10-1074. Instead, the methods were compared, and consensus-derived cut-offs were set, which resulted in concordant susceptibility assessments for 84% of the participants. In conclusion, our study underlines the importance of the chosen method and cut-off when assessing an individual’s virus susceptibility to HIV-1 bNAbs. Furthermore, we propose cut-offs for bNAb susceptibility to guide the design of future clinical trials.
No takes yet. Share an insight, caveat, or question.
Pahus et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: